SEC Charges Pfizer with FCPA Violations

FOR IMMEDIATE RELEASE
2012-152


The SEC alleges that employees and agents of Pfizer’s subsidiaries in Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia made improper payments to foreign officials to obtain regulatory and formulary approvals, sales, and increased prescriptions for the company’s pharmaceutical products. They tried to conceal the bribery by improperly recording the transactions in accounting records as legitimate expenses for promotional activities, marketing, training, travel and entertainment, clinical trials, freight, conferences, and advertising.

Additional Materials

- SEC Complaint Against Pfizer
- SEC Complaint Against Wyeth
- More SEC FCPA Cases

The SEC separately charged another pharmaceutical company that Pfizer acquired a few years ago – Wyeth LLC – with its own FCPA violations. Pfizer and Wyeth agreed to separate settlements in which they will pay more than $45 million combined to settle their respective charges. In a parallel action, the Department of Justice announced that Pfizer H.C.P. Corporation agreed to pay a $15 million penalty to resolve its investigation of FCPA violations.

“Pfizer subsidiaries in several countries had bribery so entwined in their sales culture that they offered points and bonus programs to improperly reward foreign officials who proved to be their best customers,” said Kara Brockmeyer, Chief of the SEC Enforcement Division’s Foreign Corrupt Practices Act Unit. “These charges illustrate the pitfalls that exist for companies that fail to appropriately monitor potential risks in their global operations.”

According to the SEC’s complaint against Pfizer filed in U.S. District Court for the District of Columbia, the misconduct dates back as far as 2001. Employees of Pfizer’s subsidiaries authorized and made cash payments and provided other incentives to bribe government doctors to utilize Pfizer


9/4/2012
products. In China, for example, Pfizer employees invited “high-prescribing
doctors” in the Chinese government to club-like meetings that included
extensive recreational and entertainment activities to reward doctors’ past
product sales or prescriptions. Pfizer China also created various “point
programs” under which government doctors could accumulate points based
on the number of Pfizer prescriptions they wrote. The points were
redeemed for various gifts ranging from medical books to cell phones, tea
sets, and reading glasses. In Croatia, Pfizer employees created a “bonus
program” for Croatian doctors who were employed in senior positions in
Croatian government health care institutions. Once a doctor agreed to use
Pfizer products, a percentage of the value purchased by a doctor’s
institution would be funneled back to the doctor in the form of cash,
international travel, or free products.

According to the SEC’s complaint, Pfizer made an initial voluntary disclosure
of misconduct by its subsidiaries to the SEC and Department of Justice in
October 2004, and fully cooperated with SEC investigators. Pfizer took such
extensive remedial actions as undertaking a comprehensive worldwide
review of its compliance program.

The SEC further alleges that Wyeth subsidiaries engaged in FCPA violations
primarily before but also after the company’s acquisition by Pfizer in late
2009. Starting at least in 2005, subsidiaries marketing Wyeth nutritional
products in China, Indonesia, and Pakistan bribed government doctors to
recommend their products to patients by making cash payments or in some
cases providing BlackBerrys and cell phones or travel incentives. They often
used fictitious invoices to conceal the true nature of the payments. In Saudi
Arabia, Wyeth’s subsidiary made an improper cash payment to a customs
official to secure the release of a shipment of promotional items used for
marketing purposes. The promotional items were held in port because
Wyeth Saudi Arabia had failed to secure a required Saudi Arabian
Standards Organization Certificate of Conformity.

Following Pfizer’s acquisition of Wyeth, Pfizer undertook a risk-based FCPA
due diligence review of Wyeth’s global operations and voluntarily reported
the findings to the SEC staff. Pfizer diligently and promptly integrated
Wyeth’s legacy operations into its compliance program and cooperated fully
with SEC investigators.

In settling the SEC’s charges, Wyeth neither admitted nor denied the
allegations. Pfizer consented to the entry of a final judgment ordering it to
pay disgorgement of $16,032,676 in net profits and prejudgment interest of
$10,307,268 for a total of $26,339,944. Wyeth also is required to report to
the SEC on the status of its remediation and implementation of compliance
measures over a two-year period, and is permanently enjoined from further
violations of Sections 13(b)(2)(A) and 13(b)(2)(B) of the Securities
Exchange Act of 1934. Wyeth consented to the entry of a final judgment
ordering it to pay disgorgement of $17,217,831 in net profits and
prejudgment interest of $1,658,793, for a total of $18,876,624. As a Pfizer
subsidiary, the status of Wyeth’s remediation and implementation of
compliance measures will be subsumed in Pfizer’s two-year self-reporting
period. Wyeth also is permanently enjoined from further violations of
Sections 13(b)(2)(A) and 13(b)(2)(B) of the Exchange Act. The settlements
are subject to court approval.

The SEC’s investigation was conducted by Michael Catoe and Charles Cain
of the Enforcement Division’s FCPA Unit. The SEC acknowledges the assistance of the U.S. Department of Justice’s Criminal Division’s Fraud Section and the Federal Bureau of Investigation in this matter.

# # #